Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.72 |
| ▸ | MMP9 | P14780 | 4/20 | 0.72 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.72 |
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13857135 | 0.86 | ADAM17 (0.70) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL27625488 | 0.85 | MMP2 (0.67) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL2403666 | 0.84 | RAB9A (0.59) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL5294261 | 0.82 | ADAM17 (0.69) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL4927452 | 0.82 | MMP2 (0.64) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL31320649 | 0.82 | MMP2 (0.64) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL9436016 | 0.82 | KDM4E (0.54) | MMP2MMP9ADAM17MAOBCA9 | |
| SCHEMBL29089438 | 0.82 | ADAM17 (0.64) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL29569054 | 0.82 | MMP2 (0.54) | MMP2MMP9ADAM17MAOBCA12 | |
| SCHEMBL10769815 | 0.81 | MMP2 (0.59) | MMP2MMP9ADAM17MAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322180-A | Coumarin pyrazolone fluorescent probe and preparation method and application thereof | 南京医科大学康达学院 | 2022-11-11 | — | — | CN | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| WO-2007082178-A2 | PROSTAGLANDIN REDUCTASE INHIBITORS | ABGENOMICS CORPORATION (TW) | 2007-07-19 | — | — | WO | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-0538053-A1 | Separation and analysis | GEC-MARCONI LIMITED (GB) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124688-A1 | Prostaglandin reductase inhibitors | PTGIR, PTGDR, PTGDR2 | MMP2 929/4885MMP9 1646/4885ADAM17 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.